MLAB

Mesa Laboratories, Inc.

$95.82

2.83

(3.04%)

Exchange:	NASDAQ
Market Cap:	522.74M
Shares Outstanding:	3.482M

Overview

Earnings

Financials

Valuation

Chart

About The Company

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company’s Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment’s solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company’s Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Click to read more…

Revenue Segmentation

EPS

View full analyst estimates

Earnings Call

No transcript or summary available for this symbol.

Income Statement

Balance Sheet

Cash Flow Statement

Analyst Estimates

Income Statement

(* All numbers are in thousands)

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
? Revenue	71,330	84,659	93,665	96,179	103,135	117,687	133,937	184,335	219,080	216,187
? Cost Of Revenue	27,938	33,246	40,426	41,560	42,219	52,754	46,923	75,245	85,387	82,937
? Gross Profit	43,392	51,413	53,239	54,619	60,916	64,933	87,014	109,090	133,693	133,250
? Research And Development Expenses	3,294	3,972	4,157	3,539	3,506	6,355	10,388	15,767	20,490	19,300
? General And Administrative Expenses	17,058	23,618	22,814	26,255	31,295	37,826	45,697	60,311	72,444	72,867
? Selling And Marketing Expenses	7,176	7,500	9,955	8,823	8,260	12,910	18,480	28,310	37,439	38,625
? Operating Expenses	27,528	35,090	36,926	38,617	43,061	57,141	74,656	104,388	130,373	406,554
? Net Interest Income	0	0	0	0	0	0	0	0	0	0
? Interest Income	0	0	0	0	1,720	960	107	3,885	4,770	0
? Interest Expense	0	0	0	0	0	5,504	8,024	3,885	3,709	5,697
? Depreciation And Amortization	5,656	7,174	8,737	9,471	9,469	12,871	17,472	25,068	33,134	31,574
? EBITDA	21,520	23,497	25,050	9,772	18,092	8,090	12,358	29,770	36,454	-238,376.999
? EBIT
? Operating Income	15,864	16,323	16,313	2,183	9,781	-4,900	-5,302	-20,366	-30,504	-272,075
? Income Before Tax	15,347	15,555	14,296	301	8,623	3,433	2,303	3,574	-389	-275,648
? Income Tax Expense	5,764	4,386	3,113	3,263	1,139	2,084	-971	1,703	-1,319	-21,402
? Net Income From Continuing Operations
? Net Income	9,583	11,169	11,183	-2,962	7,484	1,349	3,274	1,871	930	-254,246
? EPS (Earnings Per Share)	2.720	3.100	3.040	-0.790	1.950	0.320	0.660	0.360	0.170	-47.200
? EPS Diluted	2.630	2.970	2.910	-0.790	1.860	0.310	0.640	0.350	0.170	-47.200
? Weighted Average Shares Outstanding	3,521	3,605	3,679	3,749.367	3,839	4,200	4,975	5,212	5,321	5,386
? Weighted Average Shares Outstanding Diluted	3,650	3,757	3,844	3,770	4,033	4,371	5,124	5,335	5,361	5,386
	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD

Balance Sheet

(* All numbers are in thousands)

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
? Cash And Cash Equivalents	2,034	5,695	5,820	5,469	10,185	81,380	263,865	49,346	32,910	28,214
? Short Term Investments	0	0	0	0	0	0	0	0	0	0
? Cash And Short Term Investments	2,034	5,695	5,820	5,469	10,185	81,380	263,865	49,346	32,910	28,214
? Net Receivables	12,145	15,313	14,319	14,302	12,516	21,132	23,787	41,224	42,551	39,055
? Accounts Receivables
? Inventory	12,420	14,017	13,873	9,228	6,772	14,230	11,178	24,606	34,642	32,674.999
? Total Current Assets	29,622	37,186	35,785	31,988	33,623	122,792	303,009	124,318	118,975	109,352
? Property Plant Equipment Net	9,598	16,628	26,002	23,593	22,225	22,066	21,998	28,620	28,149	41,437
? Goodwill	44,869	66,137	72,156	65,543	66,377	141,536	160,841	291,166	286,444	180,096
? Intangible Assets	33,231	40,797	37,790	42,850	33,219	119,871	111,741	250,117	18,226	113,752
? Long Term Investments	-79,789	-108,152	-113,500	-108,520	-246	-272,868	-273,198	0	0	0
? Total Non Current Assets	87,698	123,562	135,948	132,113	123,144	297,414	297,142	583,051	542,857	337,444
? Total Assets	117,320	160,748	171,733	164,101	156,767	420,206	600,151	707,369	661,832	446,796
? Account Payables	2,503	2,823	2,168	2,380	2,898	3,408	4,473	7,897	6,134	6,041
? Short Term Debt	3,000	3,000	1,125	1,625	2,125	1,095	14,797	6,943	8,022	2,986
? Deferred Revenue	1,314	3,026	4,117	3,921	3,965	6,814	8,777	14,581	14,407	15,478
? Total Current Liabilities	14,657	23,971	16,567	17,290	23,661	26,008	32,583	48,055	43,359	44,312
? Long Term Debt	23,250	42,250	53,675	44,635	20,613	140,278	145,675	226,289	183,272	228,311
? Deferred Revenue Non Current	0	0	0	0	0	0	0	0	0	0
? Deferred Tax Liabilities Non Current	5,122	5,419	3,554	2,621	1,077	32,549	16,275	39,224	34,028	19,780
? Total Non Current Liabilities	29,184	52,099	57,345	47,450	21,795	174,185	162,665	265,513	224,993	257,091
? Total Liabilities	43,841	76,070	73,912	64,740	45,456	200,193	193,924	313,568	268,352	301,403
? Treasury Stock
? Preferred Stock	0	0	0	0	0	0	0	0	0	0
? Common Stock	17,751	21,001	25,925	30,516	39,823	158,023	317,652	313,460	332,076	343,642
? Retained Earnings	55,962	64,828	73,656	68,281	73,303	71,930	72,459	76,675	74,199	-183,494
? Additional Paid In Capital
? Total Stockholders Equity	73,479	84,678	97,821	99,361	111,311	220,013	406,227	393,801	393,480	145,393
? Total Equity	73,479	84,678	97,821	99,361	111,311	220,013	406,227	393,801	393,480	145,393
? Minority Interest	0	0	0	0	0	0	0	0	0	0
? Total Liabilities And Total Equity	117,320	160,748	171,733	164,101	156,767	420,206	600,151	707,369	661,832	446,796
? Total Investments	-79,789	-108,152	-113,500	-108,520	-246	-272,868	-273,198	0	0	-194,056
? Total Debt	26,250	45,250	54,800	46,260	22,738	141,373	146,698	221,133	170,272	231,297
? Net Debt	24,216	39,555	48,980	40,791	12,553	59,993	-117,167	171,787	137,362	203,083
	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD

Cash Flow Statement

(* All numbers are in thousands)

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
? Net Income	9,583	11,169	11,183	-2,962	7,484	1,349	3,274	1,871	930	-254,246
? Depreciation And Amortization	5,656	7,174	8,737	9,471	9,428	12,990	17,660	25,068	33,824	31,574
? Deferred Income Tax	450	-807	-630	-2,704	-2,472	-1,971	-3,503	128	-3,494	-28,421
? Stock Based Compensation	993	1,327	1,411	1,672	4,212	5,525	9,268	11,391	12,538	11,936
? Change In Working Capital	-5,706	-2,013	-13,044	3,240	7,891	-3,137	5,252	-7,192	-17,112	5,973
? Accounts Receivables	-2,291	-1,958	994	680	1,592	-1,665	-647	-6,752	-2,121	4,940
? Inventory	-3,164	-1,202	295	2,286	2,574	414	929	-1,045	-10,182	2,563
? Accounts Payables	410	-150	-655	212	1,092	-61	967	1,370	-1,545	-97
? Net Cash Provided By Operating Activities	10,816	16,903	7,750	24,814	30,554	26,559	37,073	39,223	27,983	44,133
? Investments In Property Plant And Equipment	-2,828	-7,729	-11,605	-2,799	-1,262	-1,498	-1,992	-4,432	-4,544	-2,567
? Acquisitions Net	-20,543	-24,111	-6,800	-15,518	-4,840	-184,102	0	-300,793	-4,950	-78,739
? Purchases Of Investments	0	0	0	0	0	0	0	0	0	0
? Sales Maturities Of Investments	0	0	0	0	0	0	0	0	0	0
? Net Cash Provided By Investing Activities	0	0	0	0	0	0	0	0	0	0
? Net Debt Issuance	0	0	0	0	0	0	0	0	0	0
? Long Term Net Debt Issuance	0	0	0	0	0	0	0	0	0	0
? Short Term Net Debt Issuance	0	0	0	0	0	0	0	0	0	0
? Net Stock Issuance	0	0	0	0	0	0	0	0	0	0
? Net Dividends Paid	-2,182	-2,303	-2,355	-2,413	-2,462	-2,722	-3,165	-3,339	-3,406	-3,447
? Common Dividends Paid
? Preferred Dividends Paid	0	0	0	0	0	0	0	0	0	0
? Net Cash Provided By Financing Activities	9,072	18,620	10,708	-8,119	-21,672	231,277	146,228	52,576	-33,328	32,836
? Effect Of Forex Changes On Cash	-58	-22	72	138	-286	-1,056	1,176	-1,093	-1,597	-359
? Net Change In Cash	-3,541	3,661	125	-351	4,716	71,195	182,485	-214,519	-16,436	-4,695.999
? Cash At End Of Period	2,034	5,695	5,820	5,469	10,185	81,380	263,865	49,346	32,910	28,214
? Cash At Beginning Of Period	5,575	2,034	5,695	5,820	5,469	10,185	81,380	263,865	49,346	32,909.999
? Operating Cash Flow	10,816	16,903	7,750	24,814	30,554	26,559	37,073	39,223	27,983	44,133
? Capital Expenditure	-2,828	-7,729	-11,605	-2,799	-1,262	-1,498	-1,992	-4,432	-4,544	-2,567
? Free Cash Flow	7,988	9,174	-3,855	22,015	29,292	25,061	35,081	34,791	23,439	41,566
	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD

Analyst Estimates

(* All numbers are in thousands)

Fiscal Year	2023	2024	2025	2026	2027
Estimated Revenue (Low)	220,767.450	211,768.518	239,359.130	250,703.872	264,760.406
Estimated Revenue (High)	222,940.715	213,853.196	241,715.414	253,171.835	267,366.743
Estimated Revenue (Avg)	221,842.764	212,800	240,525	251,925	266,050
Estimated Ebitda (Low)	-22,788.812	39,001.257	-24,707.946	-25,879.012	-27,330.003
Estimated Ebitda (High)	-22,566.663	58,501.885	-24,467.089	-25,626.739	-27,063.586
Estimated Ebitda (Avg)	-22,676.580	48,751.572	-24,586.263	-25,751.561	-27,195.407
Estimated Net Income (Low)	36,802.006	380.036	41,264.415	42,963.699	44,895.119
Estimated Net Income (High)	37,273.658	1,515.963	41,793.267	43,514.309	55,930.819
Estimated Net Income (Avg)	37,035.381	948	41,528.841	43,239.004	50,412.969
Estimated SGA Expense (Low)	106,335.474	146,045.924	115,290.395	120,754.736	127,525.246
Estimated SGA Expense (High)	107,382.255	219,068.887	116,425.330	121,943.462	128,780.621
Estimated SGA Expense (Avg)	106,853.413	182,557.406	115,851.952	121,342.908	128,146.395
Estimated EPS (Avg)	6.880	7.700	7.710	8.030	9.360
Estimated EPS (High)	6.920	7.750	7.760	8.080	10.380
Estimated EPS (Low)	6.830	7.650	7.660	7.980	8.340
Number of Analysts (Estimated Revenue)	1	2	3	3	2
Number of Analysts (Estimated EPS)	1	1	2	2	2

Subscribe

Log in

Current Key Metrics

?	Revenue (TTM) :	216.187M	?	P/S (TTM) :	2.2
?	Net Income (TTM) :	-254246000	?	P/E (TTM) :	-2.09
?	Enterprise Value (TTM) :	703.396M	?	EV/FCF (TTM) :	16.36
?	Dividend Yield (TTM) :	0.01	?	Payout Ratio (TTM) :	-0.01
?	ROE (TTM) :	-1.63	?	ROIC (TTM) :	0.04
?	Net Debt (TTM) :	180.656M	?	Debt/Equity (TTM) :	1.36
?	P/B (TTM) :	3.35	?	Current Ratio (TTM) :	0.71

Forward P/E Ratios

?

Forward P/E calculated based on:

Forward P/E 1Y	Forward P/E 2Y	Forward P/E 3Y	Forward P/E 4Y	Forward P/E 5Y
13.93	12.44	12.43	11.93	10.24

SWOT Analysis

No SWOT analysis available for this stock.

MLAB

3.04

6.23

-10.87

-21.76

-27.69

7.42

-55.95

Trading Metrics:

Open:	94.28	Previous Close:	92.99
Day Low:	92.42	Day High:	96.62
Year Low:	83.68	Year High:	155.12
Price Avg 50:	111.04	Price Avg 200:	123.7
Volume:	244290	Average Volume:	69733